Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +34.35%
#2 OriginTrail OriginTrail +18.20%
#3 Purr Purr +17.28%
#4 龙虾 (Lobster) 龙虾 (Lobster) +12.28%
#5 Ethena Staked ENA Ethena Staked ENA +11.62%
#6 Wrapped XPL Wrapped XPL +11.07%
#7 DigiByte DigiByte +11.00%
#8 Collect on Fanable Collect on Fanable +10.98%
#9 Plasma Plasma +10.85%
#10 Unit Plasma Unit Plasma +10.85%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
Procaps Group S.A. Procaps Group S.A.

Procaps Group S.A.

PROC
Rank in Stocks #21710
Procaps Group S.A., established in Luxembourg in 1977, functions as a global... Procaps Group S.A., established in Luxembourg in 1977, functions as a global pharmaceutical enterprise dedicated to the creation, production, and distribution of a broad spectrum of pharmaceutical solutions. The company manufactures and markets branded prescription medications addressing diverse therapeutic needs, including women's health, pain management, dermatological conditions, digestive disorders, growth and development, cardiovascular care, vision health, central nervous system ailments, and respiratory issues. In addition to prescription drugs, Procaps supplies a suite of products for hospital use, encompassing antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare division offers an extensive portfolio of over-the-counter (OTC) products across approximately eight primary therapeutic areas such as gastrointestinal health, skincare, cough and cold remedies, pain relievers, urological support, and a variety of vitamins, minerals, and dietary supplements. These offerings cover specific categories like anti-infectives, cardiovascular health, hormonal treatments, metabolic and endocrine support, nervous system medications, ophthalmic solutions, osteoarticular products, and more. Complementing its drug offerings, Procaps provides various diabetes management solutions, including blood glucose meters, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The company also extends its expertise to third-party pharmaceutical companies through contract drug development and manufacturing services, with a particular specialization in soft gelatin capsule technologies.
Share Price
$1.01
Last synced: 2026-03-12
Market Cap
$102.08M
Change (1 day)
0.00%
Change (1 year)
-27.86%
Country
LU
Trade Procaps Group S.A. (PROC)

Category

Healthcare
Revenue for Procaps Group S.A. (PROC)
Revenue in Aug 2026 TTM: 0
According to Procaps Group S.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Procaps Group S.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN